Business Wire

Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA

MELBOURNE, Australia & SAN FRANCISCO--(BUSINESS WIRE)--Prana Biotechnology Ltd (ASX: PBT) (NASDAQ: PRAN) today announced further pre-clinical evidence for PBT434 will be presented in a poster at the ...
Business Insider

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
ALZFORUM

Multiple Strategies Seek to Banish α-Synuclein Aggregates

For synucleinopathies, which include Parkinson’s disease, multiple system atrophy, and dementia with Lewy bodies, scientists currently have no way to slow the underlying disease progression. Many ...
EurekAlert!

Why do structural differences in α-synuclein aggregates cause different pathologies?

Misfolding and aggregation of normally soluble proteins are common pathological features of many neurodegenerative diseases, including Alzheimer's, Parkinson's, Creutzfeldt-Jacob and Huntington's ...